Project Grant R01HL185283
Award Date 7/16/26
Completion Date 3/31/30
Dollars Obligated $580K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded The Johns Hopkins University $379,509 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop mesenchymal stem cell (MSC) therapies with enhanced immunosuppressive efficacy for graft-versus-host disease treatment through mechanical programming of cell microenvironments. The research focuses on identifying and providing optimal mechanical cues during MSC...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1.137883 million on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the dynamics and plasticity of the hematopoietic stem cell niche. The funded work defines niche dynamics and plasticity across development, regeneration, and hematological disease; uncovers the mechanisms regulating these processes; and develops approaches to enhance...
- The National Heart, Lung, and Blood Institute awarded The Trustees of The University of Pennsylvania $632,561 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and optimize signaling pathways that promote the maturation of pre-hematopoietic stem cells into long-term, multi-lineage adult-repopulating hematopoietic stem cells. The research focuses on transforming growth factor beta and bone morphogenetic protein signaling pathways, with emphasis on...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Trustees of Boston University $100,228 on December 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate enhancement of engraftment potential in human hematopoietic stem cells. The research addresses the challenge of preserving hematopoietic stem cell functionality during the ex vivo culture steps required for gene editing therapies. The project employs multi-modal profiling of...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $150,342 on September 30, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the mechanisms of a conserved niche endothelial program directing hematopoietic stem cell migration. The research uses high-resolution in vivo imaging in zebrafish embryos paired with human cell culture systems to investigate how bone marrow endothelial cells facilitate the...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $776,511 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. This award supports research to develop and validate a three-dimensional engineered hemogenic vascular niche model designed to elucidate the microenvironmental factors that promote hematopoietic stem...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $426,250 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac organoids with deliberate cellular heterogeneity for modeling sinus node dysfunction. The project will utilize human cardiac pacemaker organoids derived from induced pluripotent stem cells to create a human model of sinus node dysfunction, a significant heart rhythm disorder affecting pediatric patients...
- The National Heart, Lung, and Blood Institute awarded the University of Florida $597,817 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop resources for enhancing hematopoietic stem cell transplantation outcomes. The research aims to humanize the bone marrow vascular niche to study hematopoietic stem cell and vascular interactions and function. The project will establish technologies to isolate and cultivate human primary endothelial cells from bone...
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $169,160 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer hypoimmunogenic induced pluripotent stem cell (iPSC)-derived vascular cells and map immune-vascular interactions that drive immune tolerance and vascular integration. The project addresses clinical barriers to iPSC-based vascular therapies: immune rejection of allogeneic transplants and low differentiation...
- This five-year Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,117 in obligated funding beginning August 1, 2025, through July 31, 2030. The award supports a physician-scientist's career development and independent research program focused on improving hematopoietic stem and progenitor cell (HSPC) transplantation outcomes through investigation of cellular crosstalk mechanisms between...